



In the News

11/8/06 - ARRY-886 Ph1 shows stable disease in solid tumors
10/19/06 - ARRY-162 meets initial clinical objectives
6/8/06 - ARRY-886 enters Ph2 clinical trial, triggering \$3M milestone payment from AZ

Selected Collaborators

- Amgen
- AstraZeneca
- Genentech
- ICOS
- InterMune
- Japan Tobacco
- Ono Pharmaceutical
- Takeda

Analysts

William T. Ho
Bank of America
 Katherine S. Kim
C. E. Unterberg, Towbin
 Eun Yang
Jefferies & Co.
 Howard Liang
Leerink Swann
 Edward Tenthoff
Piper Jaffray
 Christopher J. Raymond
Robert W. Baird & Co.
 Paul Knight
Thomas Weisel Partners
 Maged Shenouda
UBS Investment Research
 Patrick E. Flanigan
WR Hambrecht

Major Shareholders

Wellington Management
 Kopp Investment Advisors
 OrbiMed Advisors
 Deerfield Management
 Columbia Wanger Asset Mgt
 Stephens Investment Mgt
 Cooper Hill Partners
 Pequot Capital

Array BioPharma (Nasdaq: ARRY) is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat debilitating and life-threatening diseases. Our proprietary drug development pipeline is primarily focused on the treatment of cancer and inflammatory disease and includes clinical candidates that are designed to regulate therapeutically important target proteins. In addition, leading pharmaceutical and biotechnology companies partner with Array to discover and develop drug candidates across a broad range of therapeutic areas.

NASDAQ	ARRY
Stock Price (11/27/06)	\$12.87
Market Capitalization	\$504.5 million
52 Week Range	\$6.41 - \$13.50
Shares Outstanding	39.2 million
Scientists	223/112 Ph.D.s
Cash Pos. (9/30/06)	\$96 million

Array Opportunity

- Recognized as the leading drug discovery capability in the biotech industry
- Deep pipeline of proprietary products targeting large markets in important therapeutic areas
- Building one of the most valuable small molecule clinical pipelines in the biotech industry over the next 2 years

Proprietary Drug Pipeline

Drug	Target	Indication	Marketing Rights	Lead Generation	Lead Optimization	Preclinical	Regulated Safety	IND	Phase 1	Phase 2
ARRY-886	MEK	Cancer	AstraZeneca							
ARRY-543	ErbB-2/EGFR	Cancer	Array BioPharma							
ARRY-162	MEK	Inflammation	Array BioPharma							
ARRY-797	p38	Cancer/Inflam	Array BioPharma							
ARRY-520	KSP	Cancer	Array BioPharma							
ARRY-XXX	ErbB-2	Cancer	Array BioPharma							

Our research focuses on biologic functions, or pathways, which have been identified as important in the treatment of human disease based on human clinical, genetic or preclinical data. Within these pathways, we seek to create first-in-class drugs against important therapeutic targets to treat patients with serious or life-threatening conditions, primarily in cancer, inflammatory disease and other large markets. In addition, we identify opportunities to improve upon existing therapies or drugs in clinical development by creating clinical candidates with superior, or best-in-class, drug characteristics, including efficacy, tolerability or dosing, to provide safer, more effective drugs.

ARRY-886 (AZD6244)

2006 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics - Phase 1 results showed stable disease in solid tumors; ARRY-886 was well tolerated, with rash being the DLT

Phase 2 (Initiated June 2006)

Indication Malignant melanoma (stage 3/4)
Trial Design Randomized trial comparing ARRY-886 to temozolomide
Trial Size 180 patients / 40 centers worldwide
Endpoint Progression-free survival
Other Ph 2s NSCLC, Pancreatic & Colorectal Cancers

Management AstraZeneca

ARRY-543

Array's ErbB-2 / EGFR inhibitor, ARRY-543, has demonstrated efficacy, potency and selectivity in preclinical models of human cancer.

Phase 1 (Initiated January 2006)

Trial Design Open label, multiple dose study in advanced cancer patients

1 Objectives Assess safety / tolerability; determine MTD

2 Objectives Determine PK profile; preliminary efficacy assessment

Sites Vanderbilt Univ. Medical Center & British Columbia Cancer Agency

Management Team

Robert E. Conway
CEO

Kevin Koch, Ph.D.
President & CSO

David L. Snitman, Ph.D.
COO & VP Bus. Dev.

Michael Carruthers
CFO

John R. Moore
VP & General Counsel

John A. Josey, Ph.D.
VP, Discovery Chemistry

April H. Teitelbaum, M.D.
VP, Clinical Development -
Oncology

Board of Directors

Robert E. Conway

Kevin Koch, Ph.D.

David L. Snitman, Ph.D.

Kyle A. Lefkoff
Chairman
Boulder Ventures

Francis J. Bullock, Ph.D.
Independent Consultant
Schering-Plough

Marvin H. Caruthers, Ph.D.
University of Colorado

Gil J. Van Lunsen
KPMG

Douglas E. Williams, Ph.D.
ZymoGenetics, Immunex

John L. Zabriskie, Ph.D.
Puretech Ventures
Pharmacia and Upjohn



3200 Walnut Street
Boulder, Colorado 80301
Phone: 303.381.6600
Fax: 303.386.1390
www.arraybiopharma.com
info@arraybiopharma.com

Partnered Research

Array's experienced scientific teams and proven track record of success in drug discovery make Array an ideal partner to provide clinical candidates. We create value through the synergy of our partners' knowledge and our small molecule drug discovery expertise. We continue to expand many of our partner relationships based on the successes we have demonstrated in meeting - and exceeding - research goals.


Partnered Research Summary

Track Record to Date

- Delivered 13 Clinical Candidates
- Milestones Received - Genentech, AstraZeneca, ICOS, Takeda, InterMune & Amgen
- Received \$201 Million in Research Funding
 - Over \$200 Million Potential Milestones
 - 15 Royalty Bearing Programs

Array Discovery Platform

Our scientists use the Array Discovery Platform, an integrated suite of drug discovery technologies, to create drug candidates and conduct preclinical and clinical development. A critical capability within the Array Discovery Platform is our proprietary software, which enables our scientists to share information across our company, analyze databases of existing drugs, generate novel predictive databases and design novel drugs with potential competitive advantages over current therapies. We use *in vitro* and *in vivo* predictive pharmacodynamic and pharmacokinetic models to select compounds for potential development. Early in the drug discovery process, our scientists engineer into a drug candidate desirable drug characteristics, such as improved potency, specificity and dosing regimen and reduced side effect profile. The resulting compounds are tested for safety, efficacy and metabolism to select the most promising clinical candidates.



Business Strategy

We are building a fully integrated, commercial-stage biopharmaceutical company by:

- Inventing targeted small molecule drugs that demonstrate a competitive advantage over existing therapies to fill our clinical pipeline;
- Commercializing drugs requiring a therapeutically directed sales force;
- Partnering late-stage co-development and commercialization of drugs that will be marketed to primary care physicians and that require broad distribution;
- Partnering continued research and development of select early-stage programs under which we would receive research funding, plus significant milestones and royalties; and
- Evaluating opportunities to in-license later stage clinical or commercial programs to accelerate our transition to a commercial stage biotech company.

Calendar 2006 Milestones

- Complete Phase 1b clinical trial on ARRY-886 (MEK Inhibitor)
- Complete Phase 1a clinical trial on ARRY-543 (ErbB-2 / EGFR Inhibitor)
- File 3 INDs
- Hire Chief Medical Officer
- Initiate 1 new significant drug discovery collaboration

Safe Harbor Statement:

This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve significant risks and uncertainties, including those discussed in our annual report filed on Form 10-K for the fiscal year ended June 30, 2006, and in other reports filed by Array with the Securities and Exchange Commission. In addition, we may make forward-looking statements in our press releases or in other oral or written communications with the public. These statements do not relate to historical matters and reflect our current expectations concerning future events. Therefore our actual results could differ materially from those anticipated in these forward-looking statements as a result of many factors. These factors include, but are not limited to, our ability to continue to fund and successfully progress internal research efforts and to create effective, commercially viable drugs, our ability to achieve and maintain profitability, the extent to which the pharmaceutical and biotechnology industries are willing to in-license drug candidates for their product pipelines and to collaborate with and fund third parties on their drug discovery activities, our ability to out-license our proprietary candidates on favorable terms, risks associated with our dependence on our collaborators for the clinical development and commercialization of our out-licensed drug candidates, the ability of our collaborators and of Array to meet objectives tied to milestones and royalties, our ability to attract and retain experienced scientists and management, and the risk factors set forth below under the caption "Risk Factors." We are providing this information as of the date of this report. We undertake no duty to update any forward-looking statements to reflect the occurrence of events or circumstances after the date of such statements or of anticipated or unanticipated events that alter any assumptions underlying such statements.